Denis Villeneuve Is the Next Bond Director. So What Will His 007 Look Like?
Arrival. Blade Runner 2049. Dune. And now, Bond. Amazon MGM Studios just named Québécois auteur Denis Villeneuve the next James Bond movie. (Colloquially known as "Bond 26" until a real title comes along.) Now wielding the keys to the Aston Martin, Villeneuve's involvement raises big questions about the future for the spy franchise. Mainly: What's Bond 26 going to look like?
First, the basics. Not only will this mark Villeneuve's first time working on the series in any form, but also producers Amy Pascal and David Heyman—who took the reins from the Broccolis after they ceded control to Amazon last February. It will also be the series debut of whatever actor will play James Bond next, following Daniel Craig's retirement in 2021's No Time to Die. Truly, we're in a brave new world for Bond.
"I'm a die-hard Bond fan. To me, he's sacred territory," Villeneuve said in a statement, where he added that he shared the 007 movies with his father since Dr. No with Sean Connery. "I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honor."
Villeneuve is excited to take on Bond—who wouldn't be?!—but an auteur taking over a revered film series comes with plenty of questions and speculation that a lesser-known director wouldn't necessarily attract. Amazon MGM's choice is even more interesting when you factor Villeneuve's existing body of work, a number of which are expansive science fiction features that oscillate between refined and oppressive sensibilities.
Judging by what we've broadly seen across his eleven films (beginning with his filmmaking debut August 32nd on Earth, from 1998), we might get a more tech-sophisticated Bond. You know the scenes where Bond meets Q and gets a fancy gadget? It's screaming Denis Villeneuve. And whatever the plot might be, you can bet the villain will dwell in some elaborate lair—with lots of empty space, of course—in which they pontificate their plans with deep solemnity.
If Villeneuve leans toward a version of the Bond he grew up on, though, perhaps Bond 26 will be the opposite of what Blade Runner 2049 and the Dunes looked like. (Especially if Dune: Messiah, which begins filming this summer and comes out 2026, doesn't tucker him out from architectural straight lines and gunmetal-gray color palettes.) A Bond 26 that leans into funkier retro aesthetics, found in the Connery, Lazenby, and Moore eras—or the over-the-top bombast that defined Dalton and Brosnan—or something that's all of the above, seems plausible for Villeneuve.
Back in 2015, Villeneuve told ComingSoon that directing Bond would be a dream, and that it would be an invitation to try something different. "I understand that each genre has its own specific rules, but for me, they are all movies," he said. "I'm just attracted to try to do different things, and I was very excited to make a movie that required more action. I was raised with James Bond. I love James Bond movies. I would love to do a James Bond movie one day. Action is very cinematic. I'm not someone that loves dialogue—I am someone that loves movement. Action, if it's well done, can be very poetic and meaningful."
In a 2021 appearance on the podcast Happy Sad Confused, Villeneuve called Bond "a dream to do" and "pure cinematic joy." Whether Villeneuve's definition of joy means remaking Moonraker or making Bond even more of an iconoclast in a rapidly evolving world is yet to be seen. But the Villeneuve era of Bond is already shaping up to be the biggest paradigm shift since Craig stood up on a sandbar in Casino Royale.
Basically: Get ready for Bond to get shaken, not stirred.
You Might Also Like
Kid Cudi Is All Right
16 Best Shoe Organizers For Storing and Displaying Your Kicks
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
23 minutes ago
- Associated Press
NOAA delays the cutoff of key satellite data for hurricane forecasting
The National Oceanic and Atmospheric Administration said Monday it is delaying by one month the planned cutoff of satellite data that helps forecasters track hurricanes. Meteorologists and scientists warned of severe consequences last week when NOAA said, in the midst of this year's hurricane season, that it would almost immediately discontinue key data collected by three weather satellites that the agency jointly runs with the Defense Department. The Defense Meteorological Satellite Program's microwave data gives key information that can't be gleaned from conventional satellites. That includes three-dimensional details of a storm, what's going on inside of it and what it is doing in the overnight hours, experts say. The data was initially planned to be cut off on June 30 'to mitigate a significant cybersecurity risk,' NOAA's announcement said. The agency now says it's postponing that until July 31. Peak hurricane season is usually from mid-August to mid-October. Spokespeople from NOAA and the Navy did not immediately respond to a request for more details about the update. NOAA — which has been the subject of hefty Department of Government Efficiency cuts this year — said Friday the satellite program accounts for a 'single dataset in a robust suite of hurricane forecasting and modeling tools' in the National Weather Service's portfolio. The agency's 'data sources are fully capable of providing a complete suite of cutting-edge data and models that ensure the gold-standard weather forecasting the American people deserve,' a spokesperson said. But Union of Concerned Scientists science fellow Marc Alessi told The Associated Press on Friday that detecting the rapid intensification, and more accurately predicting the likely path, of storms is critical as climate change worsens the extreme weather experienced across the globe. 'Not only are we losing the ability to make better intensification forecasts, we are also losing the ability to predict accurately where a tropical cyclone could be going, if it's in its development stages,' Alessi said. 'This data is essential. 'On the seasonal forecasting front, we would see the effects,' he added, 'but also on the long-term climate change front, we now are losing an essential piece to monitoring global warming.' ___ Alexa St. John is an Associated Press climate reporter. Follow her on X: @alexa_stjohn. Reach her at [email protected]. ___ Read more of AP's climate coverage at ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
Medscape
41 minutes ago
- Medscape
GLP-1s in Neurodegenerative Disease: Hope or Halt?
This transcript has been edited for clarity. Indu Subramanian, MD: Hi. Welcome, everyone, to Medscape. It's with great excitement that I present today a friend and colleague, Lorraine Kalia. Professor Kalia is a senior scientist at the Krembil Research Institute in Toronto, and she's also a neurologist at the University of Toronto. She's been prolific. We use her graphics many times in our slide decks. She's a great clinician and scientist, bringing you today some knowledge about clinical trials. We're excited to talk about a very hot topic, the GLP drugs. I am Dr Indu Subramanian. I'm based at UCLA. Welcome, Lorraine. Lorraine V. Kalia, MD, PhD: Hi, Indu. Thanks for having me. Why Try GLP-1 RAs in Neurodegenerative Disease? Subramanian: I was excited to read your commentary in The Lancet about the GLP-1 trials. Perhaps we could start with your thoughts and maybe a brief introduction about GLP-1 drugs and where they fit into neurodegenerative disease and Parkinson's, specifically. Kalia: I'm sure that the audience is aware of GLP-1 receptor agonists, as they've been such a hot topic with respect to treating diabetes and probably more so around treatment for obesity. They've been heavily investigated for increasing number of indications around those areas, including sleep apnea, osteoarthritis of the knees, cardiovascular disease, and in the field of neurogenerative disease, which is obviously near and dear to our hearts. They've been heavily investigated with the idea that there might be a component of insulin resistance that leads people to be at risk for neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, and that maybe repurposing these drugs for neurogenerative diseases would have some benefit. From the laboratory side, there have been tests of some of these GLP-1 receptor agonists in Parkinson's disease models that show that if you give them peripherally to animals, you can reduce the neurodegeneration of dopaminergic neurons. Importantly, there are also some epidemiologic studies that suggest if people have been treated with a GLP-1 receptor agonist, they're less likely to develop Parkinson's all of these different lines of evidence, there have been now a good number of clinical trials testing the hypothesis that treatment with a GLP-1 receptor agonist will slow the progression of Parkinson's disease. Subramanian: I think it's an exciting group to look at because we don't have to do many of the safety studies in general because we are basically repurposing a drug that's already out there. Maybe you could briefly summarize the studies and what they've shown to date. Exenatide Study Kalia: There have been a number of studies running up to this phase 3 trial of exenatide that was relatively recently published in The Lancet . Similar to the preclinical and the epidemiology work, there was a large amount of signal there that suggested some benefits. A phase 2 trial using exenatide in individuals with moderate Parkinson's disease on dopaminergic therapies showed that there was a slower progression or an increase in the number of points on their motor scores. A study using lixisenatide, which is another GLP-1 receptor agonist,also showed something similar. I, along with many others in the field, was really anticipating what the results of this phase 3 trial were going to show. It was a big study — approximately 200 participants and multicenter — which was different from the phase 2 trials, which tended to be single center. I think it was five or six UK sites. It was long for a Parkinson's disease trial at almost 2 years, solike a 96-week trial, which I think is important when we think about a slowly progressive disease. We can ask questions as to whether or not some of our earlier trials, which didn't capture any differences, was because we didn't wait long enough. This was, I'd say, a pretty good trial in terms of length. The primary outcome for this was the same primary outcome that they saw benefit with in the phase 2 trial,so learning from the phase 2 trial and hoping that that would translate to the phase 3 trial, which was basically motor scores in the off state because all of thepatients who were enrolled were on a dopaminergic therapy. Unlike the phase 2 trial, there was no difference between the placebo control group and the group that received could ask, was that the right measure? We always have discussions around whether or not our outcome measures are sensitive enough or was that the right one. All of the secondary outcome measures — so all of the other measures, including the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, Montreal Cognitive Assessment (MoCA) score, quality of life scores, and how muchdopaminergic therapies had to be changed over the course of the trial — were absolutely identical between the two groups. There was no signal in any of the secondary or exploratory outcomes, so really negative across the board. Subramanian: I think the patients have been really hungry to see the results of this trial. I don't know about you, but I think everyone and their mother is on a GLP drug, it seems like. People have been trying to use some of these even off-label and acquire them and get themmade in compounding pharmacies. Patient Guidance Kalia: I think that's a great point that you bring up that I thought was useful for discussion also. If patients come to you and ask to be put on a GLP-1 receptor agonist, even though there's no indication for it, then my answer — especially now with a negative trial — would be that there's really no indication to do that, especially in the context of no benefit and potential for side effects. Subramanian: Let's talk about the side effects, because I think one of the things that I've been really interested in is weight loss in Parkinson's. We've been doing some work on women, especially Asian women like you and me, who may have lower body mass and end up getting dyskinetic and sometimes getting into the cycle of losing weight and getting very bone fractures, fall risk, and other issues can come up. Maybe we could talk a little bit about your sense of that. Kalia: Everyone's concern around the GLP-1 receptor agonists in a Parkinson's disease population where you don't want people losing weight, per se, was if that's going to be the side effect of these drugs, it's going to increase frailty. At least in this trial with exenatide, the extended-release version in the phase 3 trial, there wasn't as much weight loss as had been seen in prior studies. One could wonder if maybe that was then an indicator of insufficient dosing. That's just speculation. I guess, as expected, for anyone who's familiar with the side effects around GLP-1 receptor agonists, there were gastrointestinal (GI) side effects, so GI upset and diarrhea, and then nonspecific things. Overall, if we were to look at the silver lining, the trial demonstrated, as did the phase 2 trial, that exenatide can be well tolerated in a Parkinson's disease population. Whether that's the case for all GLP-1 receptor agonists is not known. Perhaps for some that are much more efficacious at weight loss, we will still probably need to be cautious as to that kind of side effect or that effect that people want in a non-Parkinson's disease population, and how that might have negative ramifications in a Parkinson's disease population. The 'Lessebo' Effect Subramanian: We do have to weigh the risks and the benefits, and I don't personally see an indication at the moment either. You brought up also, a point about lessebo. Maybe we could talk about lessebo. What is that? Kalia: I brought that up, again, entirely as speculation. It was related to the amount of weight loss seen in this trial that was not as much as anticipated. Obviously, participants in these clinical trials are very likely going to knowsomething, if not a lot, about GLP-1 receptor agonists. Knowing that they're in a placebo-controlled trial and knowing that they might be on placebo vs exenatide, if they weren't actually experiencing weight loss, they may have assumed,and so then the effects that come with a placebo effect are absent. That's entirely speculation on my part to try to explain why maybe the differences seen in this trial were not as obvious as they had been in the previous phase 2 trial. Subramanian: There's so much to consider and so much complexity. Thank you so much, Lorraine, for joining us today. It's been a pleasure to talk about this rather complex area and get your insights. Kalia: Thanks for having me. It was a great chat.
Fox News
an hour ago
- Fox News
William Shatner still battles 'difficult' health condition caused by 'Star Trek' mishap
William Shatner is getting candid about a "difficult" health condition he's battled since the 90s. In a new promotional video for the nonprofit Tinnitus Quest, the "Star Trek" star, 94, opened up about the challenges he's faced while living with tinnitus for over three decades. "My own journey with tinnitus started when I was filming a 'Star Trek' episode called 'Arena,' and I was too close to the special effects' explosion, and the result was that I was left with permanent tinnitus," Shatner said in the video. "And over the years, I've had many ups and downs with my tinnitus, and I know from firsthand experience just how difficult it can get," he added. Tinnitus is a condition in which a person can experience ringing or other noises in one or both ears, according to the Mayo Clinic. Tinnitus is a common problem and can affect about 15% to 20% of people, and is especially common in older adults. Shatner — who was diagnosed with tinnitus in the 1990s — shared that while "there are no effective treatments" for the condition, he remains focused on trying to raise money for a cure. Last year, the legendary actor shared the secret to remaining youthful in his 90s. "Just staying engaged in life, to stay curious. But the luck has a lot to do with it in your health," he told People at the time. "Your life's energy, the soul energy of your body is a product of health," he added. "If you're sick, you can't be energetic. You're dying. So my luck has been, I've been healthy all my life." The actor, who starred in the original "Star Trek" show from 1966 to 1969, prides himself on still being "energetic." As far as his longevity in the entertainment industry, Shatner previously told Fox News Digital, "It's luck." "It's the luck of being healthy," he added. "I think that's the first thing … I've had things happen, but nothing debilitating over a period of time. So having the life force within me, is probably, mostly, what it's all about."
